With anatomic-based planning, it may be difficult to differentiate between non-viable (low metabolic activity) and viable (high metabolic activity) parts of a tumor. This might result in target volumes that are too small or too large and can lead to radiation dose being delivered to healthy tissue. Molecular Imaging helps overcome these challenges by distinguishing between high metabolically active tumor regions and areas of necrosis for early, precise target volume definition, allowing the physician to improve dose escalation and treatment monitoring.